| Characteristics | Fatigue | Fatigue | p-value | ||
|---|---|---|---|---|---|
| Non to mild | Moderate to severe | ||||
| VAS score <57 | VAS score >57 | ||||
| n=520 | n=542 | ||||
| n | n | ||||
| Female, n (%) | 253 (48.7%) | 520 | 358 (66.1%) | 542 | <0.001 |
| Age, yrs | 53.0 (44.0–62.0) | 520 | 52.0 (42.8–60.0) | 542 | 0.070 |
| Disease duration, yrs | 6.0 (3.0–11.5) | 449 | 5.0 (2.0–10.0) | 456 | 0.022 |
| C-reactive protein, mg/L | 3.0 (1.0–6.0) | 421 | 4.0 (2.0–7.0) | 464 | 0.008 |
| Patient global assessment, 0–100 mmVAS | 27.0 (15.0–43.0) | 520 | 75.5 (61.0–86.0) | 542 | <0.001 |
| Doctors global assessment, 5-grade Likert scale | 7.0 (3.0–15.0) | 432 | 14.0 (7.0–14.0) | 438 | <0.001 |
| PDQ pain score | 9.0 (6.0–14.0) | 520 | 17.0 (13.0–23.0) | 542 | <0.001 |
| DAS28-CRP | 2.3 (1.8–2.9) | 400 | 3.5 (2.6–4.4) | 418 | <0.001 |
| HAQ, 0–3 | 0.4 (0.1–0.8) | 507 | 1.1 (0.8–1.6) | 530 | <0.001 |
All values are median (Q1-Q3) unless otherwise indicated. VAS; visual analogue scale, PDQ; pain assessment questionnaire, DAS28-CRP; disease activity score-C-reactive protein, HAQ; health assessment questionnaire.